Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT017 single ascending dose study in healthy volunteers
NL-OMON44567Phase 1Active, not recruiting
- Sponsor
- Acticor Biotech
- Start
- Oct 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke and brain infarction comparing ACT017 with Placebo (2 arms). Primary endpoints: Adverse events, Clinical laboratory results and 6 more. Started Oct 2017; status: active, not recruiting.
02
Drugs
glenzocimab
03
Conditions
ischemic strokebrain infarction
Beyond the preview
Go deeper on NL-OMON44567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44567.